SLDB vs SRPT
SLDB: A gene therapy company advancing a pipeline of treatments for rare neuromuscular and cardiac diseases including Duchenne muscular dystrophy, Friedreich's ataxia, and cardiomyopathy. SRPT: A biopharmaceutical leader in genetic medicine, specializing in innovative RNA-targeted therapies and gene treatments for Duchenne muscular dystrophy and rare genetic disorders.
Side-by-side fundamentals
| Metric | SLDB | SRPT | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $8.10 | $15.82 | |
| Market cap as of 2026-07-23 | $808M | $1.7B | |
| P/E as of 2026-07-23 | n/a | 26.31 | |
| PEG as of 2026-07-23 | n/a | -23.53 | |
| Net margin as of 2026-07-23 | -588.3% | +3.0% | SRPT higher |
| Gross margin as of 2026-07-23 | n/a | +70.5% | |
| Operating margin as of 2026-07-23 | -591.1% | -1.1% | SRPT higher |
| ROE as of 2026-07-23 | -74.5% | +4.9% | SRPT higher |
| ROA as of 2026-07-23 | -62.0% | +1.9% | SRPT higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.56 | SLDB lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | -2.2% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +33.1% | |
| Beta as of 2026-07-23 | 2.40 | 0.19 | |
| 1-year return as of 2026-07-22 close | +32.8% | +16.2% | SLDB higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.